Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Hepatitis B Virus Testing Market: By Test Type, Anti-hepatitis B Surface Antibody Test, Hepatitis B Core Antigen Test, Anti-hepatitis B Core Antibody Test, HBV DNA Test, and Others), By Techniques, Enzyme-linked immunosorbent assay and Others), By End User and Geography
Hepatitis B virus testing market size was valued at US$ 949.07 million in 2023 and is expected to reach US$ 1319.44 million by 2030, at a CAGR of 6.5% from the period 2024-2030. Increase in liver cancer cases, growing aging population, healthcare spending, and urbanization. leading to better monitoring and screening procedures. In addition, government initiatives to grow awareness in public, increase in R&D spending by companies, and growing demand for biomarker tests due to their accuracy are expected to boost the market during the forecast period.
However, factors such as lack of awareness in developing countries, stringent regulatory rules, rigid competition, and high cost of testing are expected to hamper the market over the forecast period. Hepatitis B is a liver disease caused by the Hepatitis B virus (HBV). Hepatitis B viral infection control ranges can form mild infection which lasts a few weeks and a chronic infection that may lead to liver disorders and even death. Hepatitis B is one of the global health problems. Hepatitis B can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer. The virus is transmitted through contact with the blood or other body fluids of an infected person.
According to the World Health Organization, 257 million people are living with hepatitis B virus infection worldwide, and in 2015, 887,000 hepatitis B resulted in deaths. this report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities, and possible challenges to the key stakeholders operating in the market. In addition, The global market report includes human demographics; regulatory scenario, and competition analysis with a vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed the global market to better equip clients with possible investment opportunities across the regions (regional Investment hot spots) and market unmet needs (Product opportunities).
Study Period
2024-2030Base Year
2023CAGR
6.5%Largest Market
North-AmericaFastest Growing Market
Asia Pacific
The rise in global hepatitis B prevalence might be attributed to the growth of the hepatitis B diagnostic testing market. According to the World Health Organization, it affects more than 300 million people worldwide. Furthermore, it is well-known that its frequency is particularly high in the Western Pacific and African regions. Perinatal transmission and horizontal transfer by infected blood are both prominent causes of infection in endemic areas. Increased public awareness, as well as increased government and non-profit initiatives, all contribute to the market's growth. As people become more aware of the disease, it gets diagnosed earlier. Hepatitis B diagnostic tests are in high demand as a result of this. The global hepatitis B diagnostic testing market is expected to be hampered by a lack of common recommendations for hepatitis B diagnosis.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 949.07 million |
Market Size in 2030 |
US$ 1319.44 million |
Market CAGR |
6.5% |
By Test Type |
|
By Techniques |
|
By End User |
|
Download Free Sample Report
The global hepatitis b virus testing market size was valued at US$ 949.07 million in 2023 and is projected to grow at a CAGR of 6.5% from 2024 to 2030.
The hepatitis b virus testing market key players are: Onsite Lab Holding AG (MedMira Inc.) (Switzerland) F. Hoffmann-La Roche (Switzerland) Abbott Laboratories (U.S.) Siemens AG (Siemens Healthcare GmbH) (Germany) Fisher Bioblock Bolding (Thermo Fisher Scientific) (France) Innovita biological technology Co. Ltd. (China) General Biologicals Corporation (Taiwan) Nantong Diagnos Biotechnology Co. Ltd. (China) Blue Cross Bio-Medical Co. Ltd. (China) BioGenex (U.S.) Abnova Corporation (U.S.)
The hepatitis b virus testing market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
Key Market Players